These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 14870515)

  • 21. [Psychosocial treatment plus drug prophylaxis. Fewer recurrences after alcohol withdrawal].
    Smolka MN; Kiefer F; Mann K
    MMW Fortschr Med; 2003 Sep; 145(35-36):45. PubMed ID: 14584210
    [No Abstract]   [Full Text] [Related]  

  • 22. Preclinical and clinical pharmacology of alcohol dependence.
    Tambour S; Quertemont E
    Fundam Clin Pharmacol; 2007 Feb; 21(1):9-28. PubMed ID: 17227441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does the alcoholic's remedy come in a pill?
    Gordon SM
    Behav Healthc Tomorrow; 2001 Aug; 10(4):SR29-30, SR34. PubMed ID: 11496583
    [No Abstract]   [Full Text] [Related]  

  • 24. [Efficient prevention of relapse with acamprosate].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2000 Jun; 23(6):206-7. PubMed ID: 10950666
    [No Abstract]   [Full Text] [Related]  

  • 25. [Preventing recurrence after alcohol withdrawal treatment with drugs. Reducing the drive to drink].
    MMW Fortschr Med; 2003 May; 145(19):56. PubMed ID: 12813988
    [No Abstract]   [Full Text] [Related]  

  • 26. Expectancy in double-blind placebo-controlled trials: an example from alcohol dependence.
    Colagiuri B; Morley K; Boakes R; Haber P
    Psychother Psychosom; 2009; 78(3):167-71. PubMed ID: 19270472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials.
    Snyder JL; Bowers TG
    Am J Drug Alcohol Abuse; 2008; 34(4):449-61. PubMed ID: 18584575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Deficits in preventing recurrence in alcoholic patients. Withdrawal--and immediately back to the bottle].
    MMW Fortschr Med; 2003 Jan; 145(1-2):55. PubMed ID: 12638445
    [No Abstract]   [Full Text] [Related]  

  • 29. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.
    Rösner S; Leucht S; Lehert P; Soyka M
    J Psychopharmacol; 2008 Jan; 22(1):11-23. PubMed ID: 18187529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial.
    Morley KC; Teesson M; Reid SC; Sannibale C; Thomson C; Phung N; Weltman M; Bell JR; Richardson K; Haber PS
    Addiction; 2006 Oct; 101(10):1451-62. PubMed ID: 16968347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In alcohol-treated rats, naloxone decreases extracellular dopamine and increases acetylcholine in the nucleus accumbens: evidence of opioid withdrawal.
    Rada P; Johnson DF; Lewis MJ; Hoebel BG
    Pharmacol Biochem Behav; 2004 Dec; 79(4):599-605. PubMed ID: 15582668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators.
    Ooteman W; Naassila M; Koeter MW; Verheul R; Schippers GM; Houchi H; Daoust M; van den Brink W
    Addict Biol; 2009 Jul; 14(3):328-37. PubMed ID: 19523047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prescription procedures in medication for relapse prevention after inpatient treatment for alcohol use disorders in Switzerland.
    Buri C; Moggi F; Giovanoli A; Strik W
    Alcohol Alcohol; 2007; 42(4):333-9. PubMed ID: 17517820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acamprosate for alcohol dependence?
    Drug Ther Bull; 1997 Sep; 35(9):70-2. PubMed ID: 9350085
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacotherapy of alcohol use disorders.
    Buonopane A; Petrakis IL
    Subst Use Misuse; 2005; 40(13-14):2001-20, 2043-8. PubMed ID: 16282090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increasing leptin precedes craving and relapse during pharmacological abstinence maintenance treatment of alcoholism.
    Kiefer F; Jahn H; Otte C; Demiralay C; Wolf K; Wiedemann K
    J Psychiatr Res; 2005 Sep; 39(5):545-51. PubMed ID: 15992564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The glycine reuptake inhibitor Org24598 and acamprosate reduce ethanol intake in the rat; tolerance development to acamprosate but not to Org24598.
    Lidö HH; Marston H; Ericson M; Söderpalm B
    Addict Biol; 2012 Sep; 17(5):897-907. PubMed ID: 21955180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acamprosate for the treatment of alcohol dependence.
    Boothby LA; Doering PL
    Clin Ther; 2005 Jun; 27(6):695-714. PubMed ID: 16117977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute and chronic alcohol injections increase taurine in the nucleus accumbens.
    De Witte P; Dahchour A; Quertemont E
    Alcohol Alcohol Suppl; 1994; 2():229-33. PubMed ID: 8974341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?
    Richardson K; Baillie A; Reid S; Morley K; Teesson M; Sannibale C; Weltman M; Haber P
    Addiction; 2008 Jun; 103(6):953-9. PubMed ID: 18482418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.